Ibogaine for Bipolar Disorder

Ibogaine for Bipolar Disorder

Bipolar disorder and addiction frequently travel together — epidemiological studies consistently find substance use disorders far more common in bipolar I and II than in the general population, with lifetime estimates varying widely by sample and diagnostic method. We are not quoting a single percentage here because the published range is too wide for one number to be honest. That overlap puts ibogaine on the radar for a population that desperately needs better options. The question is whether ibogaine is a realistic path for someone managing bipolar disorder, or whether the risks outweigh the potential benefits.

The honest answer: it depends on the individual, and the details matter enormously.

What Ibogaine Does in the Brain

Ibogaine is an indole alkaloid derived from the root bark of Tabernanthe iboga, a shrub native to Central Africa. Its pharmacology is unusually complex — it acts simultaneously on opioid receptors, serotonin transporters (SERT), dopamine transporters, NMDA receptors, and sigma-2 receptors. This multi-target profile is part of why it can interrupt opioid withdrawal in a way that single-mechanism drugs cannot match.

For mood disorders specifically, two mechanisms are most relevant:

SERT inhibition — Ibogaine inhibits the serotonin transporter, similar in mechanism (though not identical in profile) to SSRIs. This raises extracellular serotonin and may contribute to the antidepressant-like effects some patients report following treatment.

GDNF and BDNF upregulation — Ibogaine increases glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF). Both are implicated in neuroplasticity, and BDNF deficiency has long been associated with depressive episodes.

Noribogaine, the long-acting metabolite — After ibogaine is metabolized, noribogaine remains active for weeks, selectively inhibiting SERT with far greater affinity than the parent compound. This extended serotonergic effect is likely responsible for the sustained mood changes some patients report long after the acute experience ends.

The Bipolar-Specific Research Gap

There is no randomized controlled trial examining ibogaine specifically in bipolar populations. Most clinical research to date has focused on opioid use disorder (OUD), with mood data collected as secondary outcomes.

A 2017 survey by Dr. Thomas Kingsley Brown and Kenneth Alper published in Journal of Psychoactive Drugs found that many patients with co-occurring mood symptoms reported improvements following ibogaine treatment. A 2021 observational study at Stanford (Glidden et al.) tracked veterans receiving ibogaine at a licensed clinic in Mexico — significant reductions in depression and PTSD symptoms were reported at one-month follow-up, but the study excluded patients with active bipolar I disorder.

What Bipolar Patients Need to Screen For

Bipolar disorder raises two specific questions that a general screening will not necessarily surface, and both need to be on the table before treatment is considered.

If you or someone close to you needs help right now, SAMHSA’s national helpline is free, confidential and staffed 24/7 on 1-800-662-HELP.

Manic Episode Induction

Any serotonergic agent carries a theoretical risk of precipitating mania in bipolar patients — this is well-documented with SSRIs and tricyclics. Ibogaine’s SERT inhibition and downstream dopaminergic effects create a plausible mechanism for manic induction, particularly in Bipolar I.

Patients currently taking lithium present a separate complication: lithium lowers the seizure threshold, and ibogaine can provoke QTc prolongation and, in rare cases, seizures. Most experienced ibogaine clinicians will not accept patients on lithium without a prolonged washout period.

Medication Review

This is the one that most often changes the answer for bipolar patients. Several atypical antipsychotics in common use — quetiapine, ziprasidone and risperidone among them — interact with ibogaine and cannot simply be continued through treatment. Any programme worth considering will work through your full medication list with you well before you travel, and will tell you plainly if the combination rules you out or requires a supervised taper first.

Never adjust psychiatric medication on your own. For how the screening and eligibility process works in full, see the Ibogaine Safety Guide.

Who With Bipolar Disorder Might Be a Candidate

Bipolar II in a depressive episode with co-occurring opioid use disorder, stable for at least 6–12 months without manic episodes, not on QTc-prolonging medications, and no structural cardiac abnormalities.

This is explicitly not a good fit for anyone in an active manic or hypomanic episode, Bipolar I patients with recent hospitalization history, anyone on lithium who cannot safely taper, or anyone with a personal or family history of Long QT Syndrome.

Getting Matched With the Right Clinic

Not every ibogaine clinic has experience managing complex psychiatric presentations. At Psychedelic Connect, we help patients find clinics that meet rigorous safety and clinical standards — and we’ll be direct with you if ibogaine isn’t the right fit given your history. Visit psychedelic-connect.com/consultation or call (866) 435-7057.

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Ibogaine carries serious cardiac risks and is contraindicated for many individuals. Consult a qualified psychiatrist and cardiologist before pursuing ibogaine treatment.